External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
Atazanavir increases plasma bilirubin levels in a concentration-dependent manner. Due to less costly and readily available assays, bilirubin has been proposed as a marker of atazanavir exposure. In this work, a previously developed nomogram for detection of suboptimal atazanavir exposure is validate...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797094946588590080 |
|---|---|
| author | Rekić, D Röshammar, D Bergstrand, M Tarning, J Calcagno, A D'Avolio, A Ormaasen, V Vigan, M Barrail-Tran, A Ashton, M Gisslén, M Äbelö, A |
| author_facet | Rekić, D Röshammar, D Bergstrand, M Tarning, J Calcagno, A D'Avolio, A Ormaasen, V Vigan, M Barrail-Tran, A Ashton, M Gisslén, M Äbelö, A |
| author_sort | Rekić, D |
| collection | OXFORD |
| description | Atazanavir increases plasma bilirubin levels in a concentration-dependent manner. Due to less costly and readily available assays, bilirubin has been proposed as a marker of atazanavir exposure. In this work, a previously developed nomogram for detection of suboptimal atazanavir exposure is validated against external patient populations. The bilirubin nomogram was validated against 311 matching bilirubin and atazanavir samples from 166 HIV-1-infected Norwegian, French, and Italian patients on a ritonavir-boosted regimen. In addition, the nomogram was evaluated in 56 Italian patients on an unboosted regimen. The predictive properties of the nomogram were validated against observed atazanavir plasma concentrations. The use of the nomogram to detect non-adherence was also investigated by simulation. The bilirubin nomogram predicted suboptimal exposure in the patient populations on a ritonavir-boosted regimen with a negative predictive value of 97% (95% CI 95-100). The bilirubin nomogram and monitoring of atazanavir concentrations had similar predictive properties for detecting non-adherence based on simulations. Although both methods performed adequately during a period of non-adherence, they had lower predictive power to detect past non-adherence episodes. Using the bilirubin nomogram for detection of suboptimal atazanavir exposure in patients on a ritonavir-boosted regimen is a rapid and cost-effective alternative to routine measurements of the actual atazanavir exposure in plasma. Its application may be useful in clinical settings if atazanavir concentrations are not available. |
| first_indexed | 2024-03-07T04:20:58Z |
| format | Journal article |
| id | oxford-uuid:cb0159ec-7c2e-46af-8b17-e9f87d52867a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:20:58Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:cb0159ec-7c2e-46af-8b17-e9f87d52867a2022-03-27T07:11:43ZExternal validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cb0159ec-7c2e-46af-8b17-e9f87d52867aEnglishSymplectic Elements at Oxford2013Rekić, DRöshammar, DBergstrand, MTarning, JCalcagno, AD'Avolio, AOrmaasen, VVigan, MBarrail-Tran, AAshton, MGisslén, MÄbelö, AAtazanavir increases plasma bilirubin levels in a concentration-dependent manner. Due to less costly and readily available assays, bilirubin has been proposed as a marker of atazanavir exposure. In this work, a previously developed nomogram for detection of suboptimal atazanavir exposure is validated against external patient populations. The bilirubin nomogram was validated against 311 matching bilirubin and atazanavir samples from 166 HIV-1-infected Norwegian, French, and Italian patients on a ritonavir-boosted regimen. In addition, the nomogram was evaluated in 56 Italian patients on an unboosted regimen. The predictive properties of the nomogram were validated against observed atazanavir plasma concentrations. The use of the nomogram to detect non-adherence was also investigated by simulation. The bilirubin nomogram predicted suboptimal exposure in the patient populations on a ritonavir-boosted regimen with a negative predictive value of 97% (95% CI 95-100). The bilirubin nomogram and monitoring of atazanavir concentrations had similar predictive properties for detecting non-adherence based on simulations. Although both methods performed adequately during a period of non-adherence, they had lower predictive power to detect past non-adherence episodes. Using the bilirubin nomogram for detection of suboptimal atazanavir exposure in patients on a ritonavir-boosted regimen is a rapid and cost-effective alternative to routine measurements of the actual atazanavir exposure in plasma. Its application may be useful in clinical settings if atazanavir concentrations are not available. |
| spellingShingle | Rekić, D Röshammar, D Bergstrand, M Tarning, J Calcagno, A D'Avolio, A Ormaasen, V Vigan, M Barrail-Tran, A Ashton, M Gisslén, M Äbelö, A External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title | External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title_full | External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title_fullStr | External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title_full_unstemmed | External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title_short | External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. |
| title_sort | external validation of the bilirubin atazanavir nomogram for assessment of atazanavir plasma exposure in hiv 1 infected patients |
| work_keys_str_mv | AT rekicd externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT roshammard externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT bergstrandm externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT tarningj externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT calcagnoa externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT davolioa externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT ormaasenv externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT viganm externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT barrailtrana externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT ashtonm externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT gisslenm externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients AT abeloa externalvalidationofthebilirubinatazanavirnomogramforassessmentofatazanavirplasmaexposureinhiv1infectedpatients |